|
BridgeBio Pharma, Inc. (BBIO) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
BridgeBio Pharma, Inc. (BBIO) Bundle
Möchten Sie den inneren Wert von BridgeBio Pharma, Inc. bestimmen? Unser (BBIO) DCF-Taschenrechner integriert reale Daten mit umfassenden Anpassungsfunktionen, sodass Sie Ihre Prognosen verfeinern und Ihre Anlagestrategien verbessern können.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.2 | 69.7 | 77.6 | 9.3 | 221.9 | 290.3 | 379.9 | 497.0 | 650.3 | 850.9 |
| Revenue Growth, % | 0 | 745.14 | 11.38 | -88.02 | 2285.27 | 30.84 | 30.84 | 30.84 | 30.84 | 30.84 |
| EBITDA | -465.7 | -533.8 | -397.4 | -565.5 | -436.8 | -290.3 | -379.9 | -497.0 | -650.3 | -850.9 |
| EBITDA, % | -5646.08 | -765.73 | -511.85 | -6078.34 | -196.86 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 3.1 | 5.8 | 6.8 | 6.5 | 6.1 | 73.8 | 96.5 | 126.3 | 165.3 | 216.3 |
| Depreciation, % | 37.43 | 8.38 | 8.72 | 69.81 | 2.74 | 25.42 | 25.42 | 25.42 | 25.42 | 25.42 |
| EBIT | -468.8 | -539.7 | -404.2 | -572.0 | -442.9 | -290.3 | -379.9 | -497.0 | -650.3 | -850.9 |
| EBIT, % | -5683.51 | -774.11 | -520.57 | -6148.15 | -199.59 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 607.1 | 787.5 | 428.3 | 434.9 | 681.1 | 290.3 | 379.9 | 497.0 | 650.3 | 850.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | 19.7 | 17.1 | 1.8 | 4.7 | 41.4 | 54.1 | 70.8 | 92.7 | 121.3 |
| Account Receivables, % | 0 | 28.33 | 22 | 18.82 | 2.13 | 14.25 | 14.25 | 14.25 | 14.25 | 14.25 |
| Inventories | .0 | -68.9 | 37.9 | .0 | .0 | -29.0 | -38.0 | -49.7 | -65.0 | -85.0 |
| Inventories, % | 0 | -98.83 | 48.85 | 0 | 0 | -10 | -10 | -10 | -10 | -10 |
| Accounts Payable | 8.9 | 11.9 | 11.6 | 10.7 | 9.6 | 137.2 | 179.5 | 234.9 | 307.3 | 402.1 |
| Accounts Payable, % | 108.44 | 17.05 | 14.89 | 114.53 | 4.33 | 47.25 | 47.25 | 47.25 | 47.25 | 47.25 |
| Capital Expenditure | -7.5 | -48.2 | -6.3 | -1.3 | -.9 | -106.2 | -139.0 | -181.9 | -237.9 | -311.3 |
| Capital Expenditure, % | -91.14 | -69.2 | -8.14 | -14.04 | -0.42046 | -36.59 | -36.59 | -36.59 | -36.59 | -36.59 |
| Tax Rate, % | 1.19 | 1.19 | 1.19 | 1.19 | 1.19 | 1.19 | 1.19 | 1.19 | 1.19 | 1.19 |
| EBITAT | -448.8 | -588.3 | -412.0 | -563.2 | -437.6 | -286.3 | -374.6 | -490.1 | -641.2 | -839.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -444.3 | -578.6 | -516.0 | -505.6 | -436.5 | -198.8 | -378.5 | -495.2 | -648.0 | -847.8 |
| WACC, % | 10.53 | 10.6 | 10.6 | 10.58 | 10.58 | 10.58 | 10.58 | 10.58 | 10.58 | 10.58 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1,801.8 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -865 | |||||||||
| Terminal Value | -10,081 | |||||||||
| Present Terminal Value | -6,098 | |||||||||
| Enterprise Value | -7,900 | |||||||||
| Net Debt | -672 | |||||||||
| Equity Value | -7,228 | |||||||||
| Diluted Shares Outstanding, MM | 186 | |||||||||
| Equity Value Per Share | -38.84 |
What You Will Get
- Real BridgeBio Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for BridgeBio Pharma, Inc. (BBIO).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates to fit your analysis.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on BridgeBio's fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections specific to BridgeBio Pharma, Inc. (BBIO).
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility in your assessments.
Key Features
- Comprehensive BridgeBio Financials: Access precise historical data and future forecasts tailored for [BBIO].
- Adjustable Forecast Parameters: Modify highlighted cells for metrics like WACC, growth rates, and profit margins.
- Real-Time Calculations: Instant updates to DCF, Net Present Value (NPV), and cash flow assessments.
- Interactive Dashboard: User-friendly charts and summaries to effectively display your valuation insights.
- Suitable for All Levels: An intuitive design crafted for investors, CFOs, and consultants alike.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered BridgeBio Pharma, Inc. (BBIO) data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for BridgeBio Pharma, Inc. (BBIO)’s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for BridgeBio Pharma, Inc. (BBIO)?
- Designed for Experts: A sophisticated tool tailored for analysts, investors, and biotech professionals.
- Accurate Data: BridgeBio’s historical and projected financials integrated for reliability.
- Flexible Scenario Analysis: Easily test various forecasts and assumptions.
- Comprehensive Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Detailed instructions to assist you throughout the calculation process.
Who Should Use This Product?
- Investors: Accurately estimate BridgeBio Pharma, Inc.'s (BBIO) fair value before making investment decisions.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis of BridgeBio Pharma, Inc. (BBIO).
- Consultants: Quickly modify the template for valuation reports tailored to BridgeBio Pharma, Inc. (BBIO) clients.
- Entrepreneurs: Acquire insights into financial modeling practices employed by leading biotech firms like BridgeBio Pharma, Inc. (BBIO).
- Educators: Employ it as a teaching resource to illustrate valuation methodologies specific to the biotech industry.
What the Template Contains
- Pre-Filled DCF Model: BridgeBio Pharma’s financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate BridgeBio Pharma’s profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.